BSG005 or placebo
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Invasive Fungal Infections
Conditions
Invasive Fungal Infections
Trial Timeline
Aug 23, 2021 → May 1, 2023
NCT ID
NCT04921254About BSG005 or placebo
BSG005 or placebo is a phase 1 stage product being developed by Biosergen for Invasive Fungal Infections. The current trial status is unknown. This product is registered under clinical trial identifier NCT04921254. Target conditions include Invasive Fungal Infections.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04921254 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Invasive Fungal Infections